Her name is Suzanne K Strayhorn. And I'm not sure why the FDA wouldn't choose her once again to head the team to respond to any and all CYDY submissions, since she has had experience with the company and the drug. This is what worries me -- far more than whether Leronlimab will have a positive effect on CRP and EN-RAGE. We have no innate reason to trust the FDA's even-handedness.